Few AIM names have changed as much in twelve months as CelLBxHealth plc (LSE:CLBX). Until October 2025 it was ANGLE plc, a liquid biopsy developer that spent more than a decade chasing clinical regulatory clearance for its Parsortix circulating tumour cell (CTC) system. After Shareholder pressure, the exit of founder-chief executive Andrew Newland, a deep restructuring, a rebrand and a heavily discounted £6.8m placing, it is now a much smaller, commercially focused CTC services company with a ticker many investors have yet to register.
The question for 2026 is whether the reset is working. Half-year results on 15 July 2026 showed the operating loss cut by 72%, cash runway into Q2 2027 and a reiterated target of at least £2.1m of Revenue this year. But the board also disclosed a material uncertainty over going concern, and the chief executive left in July. That combination is what makes CLBX either a sleeper or a trap.
Half-year results: losses slashed, but revenue still lower than a year ago
The six months to 30 June 2026 were the first full period under the restructured cost base. Revenue was £0.6m, down 25% from £0.8m in H1 2025, although Q2 revenue of £0.4m was double the £0.2m recorded in Q1. Gross Margin edged up to 61% from 59%.
The real change was in costs. Operating loss fell to £2.7m from £9.7m a year earlier, and loss after tax was £2.7m against £9.3m. Basic loss per share was 0.24p compared with 2.87p, flattered by a much larger share count after the November 2025 fundraise. The annualised operating cost base is now £6.3m and monthly cash burn is projected at £0.3m to £0.4m. Cash stood at £2.9m at 30 June 2026, down from £7.3m at the 2025 year end, after more than £1.5m of restructuring payments in the half.
Executive Chairman Jan Groen said the company had "created a leaner, more commercially focused business" and remained "focused on disciplined execution" in converting its pipeline into sustainable revenue. The commercially weighted pipeline was put at £3.5m, FY2026 revenue guidance of at least £2.1m (50% growth on FY2025) was reiterated, and positive EBITDA is targeted for 2028.
Days earlier, on 6 July 2026, chief executive Peter Collins left to pursue other opportunities barely nine months after joining as interim CEO. Groen, executive chairman since October 2025, is running the company while a successor is sought.
From ANGLE to CelLBxHealth: what the Business does now
CelLBxHealth's core asset is the patent-protected Parsortix platform, a microfluidic system that harvests intact CTCs from a standard blood sample for Downstream analysis. Unlike tests based on fragments of tumour DNA, CTCs let researchers study whole cancer cells, including protein expression, in Drug Development and biomarker research.
Revenue comes from sales of Parsortix instruments and consumables, laboratory services on customer samples, and lab-developed tests. The strategy update of 8 October 2025 abandoned the push for a broad clinical regulatory pathway in favour of the proteomics and genomics research and pharma services market. In February 2026 the company discontinued its FDA establishment licence and device listing, noting that more than 97% of installed platforms are used in research where the listing carried no commercial benefit.
Operations are consolidated at Surrey Research Park, with US laboratory space sub-let from 1 May 2026, and headcount was cut by 60% in 2025 and from 44 to 39 in Q1 2026. The company now positions itself as a partner to larger diagnostics and pharma groups: a Master Services Agreement with AstraZeneca announced on 29 May 2026, a collaboration with AdventHealth covering two clinical studies, a research Partnership with The Royal Marsden NHS Foundation Trust, and a QIAGEN co-marketing agreement signed in November 2025.
FY2025: the cost of transition
Full-year results for 2025, published on 22 June 2026, capture the scale of the reset. Revenue fell to £1.4m from £2.9m in FY2024, comprising £1.1m of product and services income and £0.3m of biopharma services. Gross margin held at 62%. The operating loss widened to £19.2m from £15.1m, inflated by restructuring charges of £1.2m in cash and £6.5m of non-cash items including a £3.8m impairment. Loss after tax was £19.5m, or 5.51p per share, against £14.2m and 4.82p. Year-end cash was £7.3m, versus £10.4m at the end of 2024.
An oversubscribed placing and subscription announced on 25 November 2025 raised approximately £6.8m gross via 680 million new shares at 1.0p, a discount of roughly 38% to the prior close of 1.6p, plus a retail offer of up to £1.0m. The weighted average share count in H1 2026 was about 1.14 billion, so at the placing price the Equity was valued at little more than £11m.
What could drive the stock next?
The most important catalyst is evidence that revenue is compounding. Guidance of at least £2.1m for FY2026 implies second-half revenue of roughly £1.5m against £0.6m in the first half, so the Q3 update and full-year figures will show quickly whether the £3.5m pipeline is converting. Work orders under the AstraZeneca framework, which has no disclosed financial terms, would be the clearest validation.
Scientific news flow continues to support the platform. On 3 August 2026 researchers at Trinity College Dublin published data showing Parsortix-harvested CTCs can assess antibody-drug conjugate targets such as TROP-2 and FRα. On 11 August 2026 a study in JCO Precision Oncology reported that Parsortix-enriched CTCs distinguished glioblastoma patients from healthy controls with 80% sensitivity and 77.3% specificity, a potential application where tissue biopsy is difficult. A permanent chief executive would remove a further overhang.
Risks investors should watch
The overriding risk is funding. Cash of £2.9m at the end of June against burn of £0.3m to £0.4m a month lasts into Q2 2027, and the directors state that additional financing through equity, Debt or licensing will be required beyond that point, with no certainty of acceptable terms. Shareholders who absorbed a 38% discount in November 2025 will be wary of further dilution.
Revenue remains tiny and lumpy: first-half sales fell year on year, and the FY2026 target depends on a strong second half. Leadership is unsettled after two CEO departures within a year, dropping the FDA listing narrows the clinical route to market, far larger liquid biopsy groups compete on circulating tumour DNA, and positive EBITDA is not targeted until 2028.
Outlook
CelLBxHealth (LSE:CLBX) has done the hard part of shrinking to fit: annualised costs are down by more than £6.6m, losses have collapsed and the science keeps attracting peer-reviewed support. It has not yet proved that a research-and-services model can grow revenue fast enough to reach self-sufficiency before cash runs low again. Second-half revenue, delivery against the £2.1m guidance, tangible orders from AstraZeneca and other partners, and the timing and terms of any further fundraise will determine whether the CLBX rebrand marks a recovery or merely a pause.






Please wait processing your request...